Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Recce Pharmaceuticals has received approval from Indonesia’s Drug and Food Authority to launch a Phase 3 clinical trial of its RECCE 327 topical gel for diabetic foot infections, marking a significant step towards commercialization and enhanced healthcare options in the region. This trial, set to be one of the largest of its kind, will involve up to 300 patients and is expected to bring near-term revenue opportunities in the ASEAN market. The initiative, supported by key stakeholders, underscores Recce’s growth trajectory and commitment to addressing critical health challenges.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Disney+ (NYSE:DIS) Hits Disney Hotels as Costs Soar
- Ford (NYSE:F) May Lose Post Office Contract Under Trump
- Gelsinger Takes to X to Support Intel’s (NASDAQ:INTC) 18A Processes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
